TrialAnnals of the rheumatic diseases2017

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.

Stanley Cohen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.